These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8772594)

  • 21. [TSH secreting adenoma of pituitary gland (TSHom) - rare cause of hyperthyroidism in pregnancy].
    Bolz M; Körber S; Schober HC
    Dtsch Med Wochenschr; 2013 Feb; 138(8):362-6. PubMed ID: 23404323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TSH producing pituitary tumor: biochemical diagnosis and long-term medical management with octreotide.
    Chayen SD; Gross D; Makhoul O; Glaser B
    Horm Metab Res; 1992 Jan; 24(1):34-8. PubMed ID: 1612557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.
    Erem C; Hacihasanoglu A; Sari A; Onder Ersöz H; Ukinç K; Fidan S
    Endocrine; 2004 Nov; 25(2):141-5. PubMed ID: 15711028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyrotropin-secreting pituitary tumor and Hashimoto's disease: a novel association.
    Iskandar SB; Supit E; Jordan RM; Peiris AN
    South Med J; 2003 Sep; 96(9):933-6. PubMed ID: 14513996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
    Gancel A; Vuillermet P; Legrand A; Catus F; Thomas F; Kuhn JM
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):421-8. PubMed ID: 8187308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review.
    Kuzu F; Bayraktaroğlu T; Zor F; G N BD; Salihoğlu YS; Kalaycı M
    Niger J Clin Pract; 2015; 18(5):693-7. PubMed ID: 26096253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
    Mannavola D; Persani L; Vannucchi G; Zanardelli M; Fugazzola L; Verga U; Facchetti M; Beck-Peccoz P
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyrotropin secreting pituitary adenoma effectively treated with octreotide.
    Fukuda T; Yokoyama N; Tamai M; Imaizumi M; Kimura H; Tominaga T; Ashizawa K; Kiriyama T; Yoshimine H; Ohishi K; Eguchi K
    Intern Med; 1998 Dec; 37(12):1027-30. PubMed ID: 9932634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.
    Katznelson L; Oppenheim DS; Coughlin JF; Kliman B; Schoenfeld DA; Klibanski A
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1318-25. PubMed ID: 1358910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
    Zhang CF; Liang D; Zhong LY
    Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas].
    Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J
    Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
    Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
    Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [New elements in the diagnosis and treatment of thyrotropic pituitary adenomas with hyperthyroidism].
    Linquette M; Cappoen JP; Mazzuca M
    Bull Acad Natl Med; 1989 Feb; 173(2):217-20; discussion 221-2. PubMed ID: 2765997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
    Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
    J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of long-term treatment with octreotide-lar in a TSH-secreting pituitary macroadenoma and secondary hyperthyroidism].
    Del Monte P; Bernasconi D; Ruelle A; Marugo A; Marugo M; Torre R
    Minerva Endocrinol; 2005 Jun; 30(2):95-9. PubMed ID: 15988405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
    Chanson P; Weintraub BD; Harris AG
    Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis.
    Alings AM; Fliers E; de Herder WW; Hofland LJ; Sluiter HE; Links TP; van der Hoeven JH; Wiersinga WM
    J Endocrinol Invest; 1998 Nov; 21(10):703-6. PubMed ID: 9854688
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversible shrinkage of a growth hormone-secreting pituitary adenoma by a long-acting somatostatin analogue, octreotide.
    Barakat S; Melmed S
    Arch Intern Med; 1989 Jun; 149(6):1443-5. PubMed ID: 2730266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.